The pharmacological activation of Nrf2 activation has been observed pharmacologically to inhibit CIS-mediated nephrotoxicity, while the absence of Nrf2 has been reported to aggravate nephrotoxicity induced by CIS. The gene discussed is NFE2L2; the disease is in situ carcinoma.